Riskpilot← Back to searchSign inGet full accessNeuraxis AB
ABActiveOrg 5591192660Årstaskogs Väg 9 AComputer programming activities · NACE 6210Est. 20171 employees
Revenue 2025
SEK 221K
-68% vs 2024
EBITDA margin
55.0%
-81% vs 2024
Equity ratio
53.5%
Financial strength
Net profit 2025
SEK 33K
-91% vs 2024
| Revenue | SEK 221K | -68% |
| EBITDA | SEK 121K | -81% |
| Net profit | SEK 33K | -91% |
| Total assets | SEK 1,2M | -11% |
| Equity | SEK 659K | -7% |
| Employees | 1 | — |
Legal name
Neuraxis AB
Org number
5591192660
Legal form
Aktiebolag
NACE code
6210 · Computer programming activities
Founded
13 juli 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamhet inom neurologi, radiologi, psykiatri och därmed förenlig verksamhet. Medicinsk IT-konsultverksamhet. Utveckling av webbaserade och mobilbaserade applikationer riktade mot läkare, patienter och forskare.
Address
Årstaskogs Väg 9 A
Email
kliron@tuta.io
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 446 | 434 | 841 | 683 | 221 |
| Staff expenses | — | −2 | −7 | −0 | — |
| EBITDA | 353 | 346 | 803 | 625 | 121 |
| Depreciation & amort. | −16 | −24 | −24 | −8 | — |
| EBIT | 337 | 322 | 779 | 617 | 121 |
| Net financials | — | — | −1 | −0 | −5 |
| Profit before tax | 258 | 241 | 582 | 460 | 67 |
| Tax | −51 | −50 | −121 | −97 | −34 |
| Net profit | 207 | 192 | 461 | 363 | 33 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 459 | 619 | 1 160 | 1 384 | 1 232 |
| Equity | 243 | 253 | 530 | 706 | 659 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 136 | 206 | 274 | 165 | 10 |
| Total debt | 136 | 206 | 274 | 165 | 10 |
EBITDA margin
55.0%
This company
15.8%
Market median
+248% vs market
20212025
Equity ratio
53.5%
This company
38.2%
Market median
+40% vs market
20212025
Return on equity
5.0%
This company
18.4%
Market median
-73% vs market
20212025
Net profit margin
15.0%
This company
8.1%
Market median
+85% vs market
20212025
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20212025
Debt / equity
0.87×
This company
0.62×
Market median
+40% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neuraxis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Dimopoulou | Deputy Board Member | 0 companies |
| Stefanos Klironomos | Board of Directors | 0 companies |